-- ============================================================================
-- SURGERY 3 MCQ BATCH 19: Breast Diseases (Questions 1081-1140)
-- Topic: Breast Diseases and Breast Cancer
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Anatomy and Physiology (1-10)
('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The breast extends from which ribs:',
'1st to 4th ribs', '2nd to 6th ribs', '4th to 8th ribs', '1st to 8th ribs', '6th to 10th ribs',
'B', 'The breast extends from the 2nd to 6th rib vertically and from the lateral border of the sternum to the midaxillary line horizontally. The axillary tail (of Spence) extends toward the axilla. Reference: Standring S. Gray''s Anatomy. 41st ed.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The main blood supply to the breast is from:',
'Only internal mammary artery', 'Internal mammary (thoracic) and lateral thoracic arteries', 'Only axillary artery', 'Only intercostal arteries', 'Subclavian artery directly',
'B', 'Breast blood supply: internal thoracic artery (perforating branches - medial), lateral thoracic artery (lateral), thoracoacromial artery (superior), and posterior intercostal arteries (posterior). Reference: Standring S. Gray''s Anatomy. 41st ed.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The primary lymphatic drainage of the breast is to:',
'Internal mammary nodes only', 'Axillary lymph nodes (75%)', 'Supraclavicular nodes only', 'Inguinal nodes', 'Cervical nodes',
'B', 'Primary lymphatic drainage: axillary nodes (75%) - Level I (lateral to pectoralis minor), Level II (behind pectoralis minor), Level III (medial to pectoralis minor/infraclavicular). Internal mammary nodes drain medial breast. Important for cancer staging. Reference: Standring S. Gray''s Anatomy. 41st ed.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Cooper''s ligaments are:',
'Muscles of the breast', 'Fibrous suspensory ligaments connecting breast to skin and chest wall', 'Blood vessels', 'Lymphatic channels', 'Nerves',
'B', 'Cooper''s (suspensory) ligaments: fibrous septa running from pectoral fascia through breast parenchyma to dermis. Provide structural support. Tumor involvement causes skin retraction/dimpling. Reference: Standring S. Gray''s Anatomy. 41st ed.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The functional unit of the breast is:',
'The nipple', 'The terminal duct lobular unit (TDLU)', 'The areola', 'Cooper''s ligament', 'The pectoralis muscle',
'B', 'Terminal duct lobular unit (TDLU): functional unit consisting of terminal duct and associated acini/lobules. Most breast pathology (both benign and malignant) arises from the TDLU. Reference: Wellings SR. Pathol Annu. 1975.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The nerve supplying sensation to the nipple-areolar complex is:',
'T2 intercostal nerve', 'T4 (fourth intercostal) lateral cutaneous branch', 'T6 intercostal nerve', 'Long thoracic nerve', 'Thoracodorsal nerve',
'B', 'The lateral cutaneous branch of the T4 intercostal nerve provides sensation to the nipple-areolar complex. Damage during surgery can cause nipple numbness. Reference: Standring S. Gray''s Anatomy. 41st ed.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The long thoracic nerve innervates:',
'Pectoralis major', 'Serratus anterior (damage causes winged scapula)', 'Latissimus dorsi', 'Deltoid', 'Trapezius',
'B', 'Long thoracic nerve (C5-7): innervates serratus anterior. Damage during axillary surgery causes winged scapula (scapula protrudes when pushing against wall). At risk in axillary dissection. Reference: Standring S. Gray''s Anatomy. 41st ed.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The thoracodorsal nerve innervates:',
'Serratus anterior', 'Latissimus dorsi', 'Pectoralis major', 'Pectoralis minor', 'Trapezius',
'B', 'Thoracodorsal nerve (C6-8): innervates latissimus dorsi. Damage during axillary surgery causes weakness in arm adduction, internal rotation, and extension. Should be identified and preserved during axillary dissection. Reference: Standring S. Gray''s Anatomy. 41st ed.',
'easy', 'knowledge'),

-- Benign Breast Diseases (9-20)
('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Fibroadenoma of the breast:',
'Is malignant', 'Is the most common benign breast tumor in young women, typically well-circumscribed and mobile', 'Only occurs after menopause', 'Is always painful', 'Requires mastectomy',
'B', 'Fibroadenoma: most common benign breast tumor in women 15-35 years. Well-circumscribed, mobile (breast mouse), rubbery, painless. Biphasic (stromal + epithelial). Usually can be observed; excision if large, growing, or patient preference. Reference: Carty NJ. Br J Surg. 1995.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Fibrocystic changes of the breast:',
'Are malignant', 'Are common benign changes often presenting with cyclic mastalgia and nodularity', 'Only occur in elderly women', 'Require mastectomy', 'Never cause symptoms',
'B', 'Fibrocystic changes: most common cause of breast lumps in premenopausal women. Includes cysts, fibrosis, adenosis. Symptoms: cyclic mastalgia, nodularity, worse premenstrually. Generally benign; only atypical hyperplasia increases cancer risk. Reference: Guray M. Histopathology. 2006.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Breast cysts:',
'Are solid tumors', 'Are fluid-filled sacs that can be diagnosed and treated by aspiration', 'Always indicate malignancy', 'Only occur in teenagers', 'Cannot be imaged',
'B', 'Simple breast cysts: fluid-filled, common in ages 35-50, often multiple and bilateral. Diagnosed by ultrasound (anechoic, smooth walls). Aspiration: diagnostic and therapeutic. Bloody aspirate or persistent mass after aspiration warrants further workup. Reference: Dixon JM. Lancet. 2007.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Mastitis typically:',
'Occurs in elderly women', 'Occurs in lactating women, presenting with breast pain, redness, and fever', 'Is malignant', 'Requires mastectomy', 'Is painless',
'B', 'Lactational mastitis: infection of breast tissue during breastfeeding. Usually S. aureus. Presents with pain, redness, warmth, fever. Treatment: antibiotics (dicloxacillin/cephalexin), continued breastfeeding/pumping. Abscess requires drainage. Reference: Amir LH. Am Fam Physician. 2014.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Breast abscess:',
'Is treated with antibiotics alone', 'Requires drainage (aspiration or incision/drainage) in addition to antibiotics', 'Is always associated with cancer', 'Never occurs during lactation', 'Resolves spontaneously',
'B', 'Breast abscess: localized collection of pus. Requires drainage (needle aspiration for small abscesses, incision and drainage for large ones) plus antibiotics. Continue breastfeeding unless incision is near nipple. Exclude inflammatory breast cancer in non-lactating patients. Reference: Dixon JM. Lancet. 2007.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Fat necrosis of the breast:',
'Is malignant', 'Is a benign condition often following trauma that can mimic carcinoma', 'Always requires mastectomy', 'Never calcifies', 'Is always symptomatic',
'B', 'Fat necrosis: benign condition following trauma, surgery, or radiation. May present as painless mass, skin retraction, calcifications - can mimic carcinoma on examination and imaging. Core biopsy confirms diagnosis. No treatment needed. Reference: Soo MS. Radiology. 1998.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Intraductal papilloma typically presents with:',
'Breast lump only', 'Unilateral bloody or serous nipple discharge', 'Bilateral discharge', 'Breast pain only', 'Skin changes only',
'B', 'Intraductal papilloma: benign epithelial tumor in lactiferous duct. Classic presentation: unilateral, spontaneous, bloody or serous nipple discharge (often from single duct). Requires duct excision for diagnosis and treatment. Reference: Leis HP. Surgery. 1989.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Gynecomastia is:',
'Male breast cancer', 'Benign proliferation of male breast glandular tissue', 'Normal male breast', 'Female breast disease', 'Always requires surgery',
'B', 'Gynecomastia: benign glandular proliferation of male breast. Causes: physiological (neonatal, pubertal, senescent), drugs (spironolactone, cimetidine, marijuana), hormonal (hypogonadism, hyperthyroidism), tumors (testicular, adrenal). Treatment addresses cause; surgery if persistent/severe. Reference: Braunstein GD. N Engl J Med. 2007.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Phyllodes tumor of the breast:',
'Is always benign', 'Is a fibroepithelial tumor that can be benign, borderline, or malignant, requiring wide excision', 'Is the same as fibroadenoma', 'Never recurs', 'Is treated with hormonal therapy',
'B', 'Phyllodes tumor: fibroepithelial tumor classified as benign, borderline, or malignant based on histology. Unlike fibroadenoma, tends to be larger, grows rapidly. Requires wide local excision (1cm margins). Malignant type may metastasize hematogenously. Reference: Tan PH. Histopathology. 2012.',
'medium', 'knowledge'),

-- Breast Cancer (21-50)
('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The most common type of invasive breast cancer is:',
'Lobular carcinoma', 'Invasive ductal carcinoma (no special type), accounting for 70-80%', 'Inflammatory carcinoma', 'Paget disease', 'Mucinous carcinoma',
'B', 'Invasive ductal carcinoma (IDC)/no special type (NST): most common (70-80%). Invasive lobular carcinoma is second (10-15%). Special types include tubular, mucinous, medullary, papillary - often have better prognosis. Reference: Malhotra GK. Cancer Biol Med. 2010.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Risk factors for breast cancer include:',
'Early menopause and multiparity', 'Female sex, age, family history, BRCA mutations, early menarche, late menopause, nulliparity', 'Male sex', 'Late menarche', 'Early first pregnancy',
'B', 'Risk factors: female sex, increasing age, family history (especially first-degree relative), BRCA1/2 mutations, early menarche (<12), late menopause (>55), nulliparity, late first pregnancy (>30), hormone therapy, obesity, alcohol, dense breasts, prior breast biopsy showing atypical hyperplasia. Reference: Colditz GA. J Natl Cancer Inst. 2006.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'BRCA1 and BRCA2 mutations:',
'Are present in most breast cancers', 'Account for 5-10% of breast cancers and significantly increase lifetime risk', 'Have no effect on cancer risk', 'Only affect men', 'Are acquired mutations',
'B', 'BRCA1/2: tumor suppressor genes involved in DNA repair. Germline mutations account for 5-10% of breast cancers. BRCA1: 50-80% lifetime breast cancer risk, also increases ovarian cancer. BRCA2: similar breast risk, also increases male breast cancer. Reference: Narod SA. Nat Rev Clin Oncol. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The most common presenting symptom of breast cancer is:',
'Nipple discharge', 'Painless breast lump', 'Breast pain', 'Skin changes', 'Arm swelling',
'B', 'Painless breast lump is the most common presentation (75-85%). Other presentations: skin changes (dimpling, peau d''orange), nipple retraction/discharge, breast asymmetry, axillary mass. Pain is uncommon initially. Screen-detected lesions are often non-palpable. Reference: Sainsbury JR. BMJ. 2000.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Peau d''orange appearance in breast cancer is caused by:',
'Skin metastasis', 'Dermal lymphatic obstruction causing skin edema', 'Inflammation', 'Fat necrosis', 'Benign changes',
'B', 'Peau d''orange (orange peel skin): caused by dermal lymphatic obstruction by tumor → skin edema with tethering at hair follicles/sweat glands → pitted appearance. Indicates locally advanced disease. Reference: Sainsbury JR. BMJ. 2000.',
'medium', 'comprehension'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Triple assessment for breast lumps includes:',
'Only imaging', 'Clinical examination, imaging (mammography/ultrasound), and tissue diagnosis (cytology/biopsy)', 'Only biopsy', 'Only clinical exam', 'MRI only',
'B', 'Triple assessment: (1) Clinical examination, (2) Imaging (mammography for >40, ultrasound for young/dense breasts), (3) Tissue diagnosis (fine needle aspiration cytology or core needle biopsy). All three required for definitive diagnosis. Reference: NICE. Early and locally advanced breast cancer guidelines. 2018.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Mammography is the standard screening modality for breast cancer because:',
'It is therapeutic', 'It can detect early cancers before they are palpable, reducing mortality', 'It is better than MRI for dense breasts', 'It is useful only for symptomatic patients', 'It has no radiation',
'B', 'Mammographic screening: detects cancers at earlier stage (smaller size, node-negative) → reduces breast cancer mortality by 20-30% in screened populations. Detects microcalcifications, masses, architectural distortion. Reference: Myers ER. Ann Intern Med. 2015.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Core needle biopsy for breast lesions:',
'Is only for palpable masses', 'Provides tissue for histology and receptor status, preferred over fine needle aspiration for solid lesions', 'Is contraindicated in cancer', 'Cannot determine receptor status', 'Is only surgical',
'B', 'Core needle biopsy: provides tissue architecture for histological diagnosis, grade, and receptor status (ER, PR, HER2). Preferred over FNA for solid lesions. Can be image-guided (ultrasound or stereotactic for calcifications). Reference: Bruening W. Ann Intern Med. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Ductal carcinoma in situ (DCIS):',
'Is invasive cancer', 'Is a pre-invasive lesion confined to the duct with no basement membrane invasion', 'Always becomes invasive', 'Metastasizes to lymph nodes', 'Requires chemotherapy',
'B', 'DCIS: proliferation of malignant cells within mammary ducts without invasion through basement membrane. Pre-invasive (Stage 0). If untreated, some progress to invasive cancer. Treatment: surgery (lumpectomy with radiation or mastectomy). No axillary staging unless invasive. Reference: Virnig BA. J Natl Cancer Inst. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Lobular carcinoma in situ (LCIS):',
'Is treated like DCIS', 'Is a risk factor for bilateral breast cancer rather than an obligate precursor', 'Always requires mastectomy', 'Is found only in men', 'Is invasive',
'B', 'LCIS: considered a risk marker (increases bilateral breast cancer risk 7-10 fold) rather than a direct precursor. Incidental finding. Management: enhanced surveillance, chemoprevention (tamoxifen), or bilateral mastectomy in high-risk patients. Reference: King TA. CA Cancer J Clin. 2015.',
'hard', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Inflammatory breast cancer is characterized by:',
'Slow growth', 'Rapid onset of erythema, warmth, peau d''orange due to dermal lymphatic invasion', 'Only nipple involvement', 'Excellent prognosis', 'Always has a palpable mass',
'B', 'Inflammatory breast cancer: aggressive, presents with rapid-onset breast erythema (≥1/3 of breast), edema (peau d''orange), warmth - mimics mastitis but no response to antibiotics. Caused by dermal lymphatic tumor emboli. No palpable mass in 30%. Poor prognosis. Reference: Robertson FM. CA Cancer J Clin. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Paget disease of the nipple:',
'Is eczema', 'Is associated with underlying breast carcinoma (DCIS or invasive) in 90% of cases', 'Is always benign', 'Only affects men', 'Resolves with topical steroids',
'B', 'Paget disease: malignant cells in nipple epidermis. Presents with nipple eczema (scaling, crusting, erythema, ulceration). Associated with underlying DCIS or invasive cancer in >90%. Unilateral nipple changes not responding to treatment warrant biopsy. Reference: Kanitakis J. J Eur Acad Dermatol Venereol. 2007.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Estrogen receptor (ER) and progesterone receptor (PR) status:',
'Have no clinical significance', 'Are important prognostic and predictive markers determining hormonal therapy benefit', 'Are only research tools', 'Determine chemotherapy response', 'Are not tested routinely',
'B', 'ER/PR status: 70-80% of breast cancers are ER-positive. ER-positive tumors: better prognosis, respond to hormonal therapy (tamoxifen, aromatase inhibitors). Tested routinely on core biopsy/surgical specimen by immunohistochemistry. Reference: Hammond ME. J Clin Oncol. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'HER2 overexpression in breast cancer:',
'Has no clinical significance', 'Indicates aggressive behavior but responds to targeted therapy (trastuzumab)', 'Is present in all breast cancers', 'Indicates good prognosis without treatment', 'Cannot be tested',
'B', 'HER2 (human epidermal growth factor receptor 2): overexpressed/amplified in 15-20% of breast cancers. Associated with aggressive behavior. Treated with targeted therapy: trastuzumab (Herceptin), pertuzumab, T-DM1. Has transformed prognosis of HER2-positive disease. Reference: Slamon DJ. N Engl J Med. 2001.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Triple-negative breast cancer:',
'Has the best prognosis', 'Lacks ER, PR, and HER2 expression, limiting targeted therapy options', 'Responds well to hormonal therapy', 'Is treated with trastuzumab', 'Is the most common subtype',
'B', 'Triple-negative breast cancer: ER-negative, PR-negative, HER2-negative (10-15% of breast cancers). Aggressive, limited targeted therapy options, higher recurrence. Treatment: chemotherapy. Often occurs in young women and BRCA1 carriers. Immunotherapy emerging for some subtypes. Reference: Foulkes WD. N Engl J Med. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Breast-conserving surgery (lumpectomy) followed by radiation:',
'Has worse survival than mastectomy', 'Has equivalent survival to mastectomy for appropriate candidates', 'Is only for benign disease', 'Requires no follow-up', 'Is contraindicated for cancer',
'B', 'Breast-conserving surgery (BCS) + radiation: equivalent survival to mastectomy in randomized trials. Indications: early-stage cancer, ability to achieve negative margins with acceptable cosmesis. Contraindications: multicentric disease, prior radiation, pregnancy, inflammatory cancer. Reference: Fisher B. N Engl J Med. 2002.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Sentinel lymph node biopsy (SLNB) in breast cancer:',
'Has replaced axillary dissection for all patients', 'Identifies the first draining node(s) to avoid routine axillary dissection if negative', 'Is only for advanced cancer', 'Requires removal of all axillary nodes', 'Is not accurate',
'B', 'SLNB: identifies sentinel node (first node draining the tumor) using blue dye and/or radiotracer. If negative, no axillary dissection needed (avoids lymphedema risk). If positive, may proceed to axillary dissection or radiation. Accuracy >95%. Reference: Krag DN. Lancet Oncol. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Axillary lymph node dissection may cause:',
'No complications', 'Lymphedema, seroma, numbness, and limited shoulder mobility', 'Improved arm function', 'Weight loss', 'Cardiac complications only',
'B', 'ALND complications: lymphedema (10-20%), seroma, intercostobrachial nerve injury (numbness of upper inner arm), shoulder dysfunction, wound infection. SLNB has lower complication rates. Lymphedema prevention: arm precautions, early treatment. Reference: DiSipio T. Lancet Oncol. 2013.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Adjuvant radiotherapy after breast-conserving surgery:',
'Is optional', 'Reduces local recurrence and is standard after lumpectomy', 'Increases mortality', 'Is only for node-positive disease', 'Replaces surgery',
'B', 'Adjuvant radiation after BCS: reduces local recurrence from ~30% to ~10%. Standard after lumpectomy. Also indicated after mastectomy for high-risk features (large tumor, positive nodes, positive margins). Reference: Early Breast Cancer Trialists'' Collaborative Group. Lancet. 2011.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Adjuvant hormonal therapy for ER-positive breast cancer:',
'Is not beneficial', 'Significantly reduces recurrence and mortality (tamoxifen or aromatase inhibitors)', 'Is given for 1 month', 'Is contraindicated', 'Is only for metastatic disease',
'B', 'Hormonal therapy: reduces recurrence by ~50% in ER-positive disease. Tamoxifen: for pre- and postmenopausal women. Aromatase inhibitors (anastrozole, letrozole, exemestane): for postmenopausal women. Duration: 5-10 years. Reference: Early Breast Cancer Trialists'' Collaborative Group. Lancet. 2011.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Tamoxifen is a:',
'Aromatase inhibitor', 'Selective estrogen receptor modulator (SERM)', 'Chemotherapy agent', 'HER2-targeted therapy', 'PARP inhibitor',
'B', 'Tamoxifen: selective estrogen receptor modulator. Blocks ER in breast tissue (antagonist) but has agonist effects in uterus (increases endometrial cancer risk) and bone (protective). Side effects: hot flashes, thromboembolism, endometrial effects. Reference: Jordan VC. Br J Pharmacol. 2006.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Adjuvant chemotherapy for breast cancer:',
'Is never needed', 'Is indicated for high-risk patients (node-positive, hormone-negative, large tumors)', 'Is only for metastatic disease', 'Replaces surgery', 'Is given for 5 years',
'B', 'Adjuvant chemotherapy: indicated for high-risk disease (node-positive, high grade, hormone receptor-negative, HER2-positive, large tumors). Regimens include anthracyclines and taxanes. Reduces recurrence and improves survival. Oncotype DX helps guide decision in some ER+/HER2- cancers. Reference: Early Breast Cancer Trialists'' Collaborative Group. Lancet. 2012.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Neoadjuvant chemotherapy in breast cancer:',
'Is never used', 'Is given before surgery to downstage tumors, allowing breast conservation or resection', 'Replaces surgery completely', 'Is only for DCIS', 'Has no role in HER2-positive disease',
'B', 'Neoadjuvant (preoperative) chemotherapy: downstages tumor (may allow BCS instead of mastectomy for large tumors), provides in vivo assessment of response, equivalent survival to adjuvant. Pathological complete response (pCR) indicates excellent prognosis. Reference: Mauri D. J Natl Cancer Inst. 2005.',
'medium', 'knowledge'),

-- Screening and Special Topics (51-60)
('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Male breast cancer:',
'Does not exist', 'Accounts for <1% of all breast cancers, often presents at later stage', 'Is more common than female breast cancer', 'Has better prognosis', 'Never requires surgery',
'B', 'Male breast cancer: <1% of all breast cancers. Risk factors: BRCA2 mutation, Klinefelter syndrome, gynecomastia, liver disease. Often presents later (less awareness, less screening). Treatment similar to female breast cancer. Reference: Giordano SH. N Engl J Med. 2018.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Prophylactic mastectomy in BRCA mutation carriers:',
'Is never performed', 'Reduces breast cancer risk by 90-95%', 'Is mandatory', 'Has no effect on risk', 'Increases cancer risk',
'B', 'Risk-reducing mastectomy in BRCA carriers: reduces breast cancer risk by 90-95%. Offered to high-risk patients after counseling. Options: total mastectomy with or without reconstruction. Alternative: enhanced surveillance with MRI/mammography. Reference: Hartmann LC. N Engl J Med. 1999.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Breast reconstruction after mastectomy:',
'Is contraindicated in cancer patients', 'Can be immediate or delayed, using implants or autologous tissue', 'Increases cancer recurrence', 'Is only cosmetic with no psychological benefit', 'Is never covered by insurance',
'B', 'Breast reconstruction: options include implant-based (expander then implant) or autologous tissue (TRAM, DIEP, latissimus flaps). Can be immediate (at mastectomy) or delayed. Does not affect oncologic outcomes. Improves quality of life and body image. Reference: Cordeiro PG. N Engl J Med. 2008.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Oncoplastic breast surgery:',
'Is only for benign disease', 'Combines oncologic resection with plastic surgery techniques for better cosmesis', 'Increases recurrence rate', 'Is contraindicated for large tumors', 'Is the same as mastectomy',
'B', 'Oncoplastic surgery: combines oncologic principles with plastic surgery techniques to achieve tumor resection with optimal cosmetic outcomes. Allows wider excisions while maintaining breast shape. May include contralateral symmetrization. Reference: Clough KB. Ann Surg. 2003.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The most common site of breast cancer metastasis is:',
'Brain', 'Bone', 'Liver', 'Lung', 'Adrenal',
'B', 'Common metastatic sites: bone (most common - especially spine, pelvis, ribs), liver, lung, brain. Bone metastases are often osteolytic. Pattern varies by subtype (triple-negative more likely visceral/brain; ER-positive more likely bone). Reference: Gong Y. J Clin Oncol. 2017.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Stage IV breast cancer:',
'Is curable with surgery', 'Has distant metastases and is generally treated with systemic therapy for palliation', 'Has the best prognosis', 'Never requires systemic therapy', 'Is only local disease',
'B', 'Stage IV: distant metastases. Generally incurable but treatable. Goals: prolong survival, maintain quality of life, palliate symptoms. Treatment: systemic therapy based on receptor status (hormonal, targeted, chemotherapy). Surgery may be palliative or for oligometastatic disease. Reference: Cardoso F. Ann Oncol. 2018.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'The 5-year survival for Stage I breast cancer is approximately:',
'30%', '50%', '70%', '>90%', '10%',
'D', '5-year survival by stage: Stage I >90%, Stage II 75-90%, Stage III 50-75%, Stage IV ~25%. Early detection through screening dramatically improves outcomes. Stage is the most important prognostic factor. Reference: Siegel RL. CA Cancer J Clin. 2020.',
'easy', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Ki-67 in breast cancer:',
'Is a hormone receptor', 'Is a proliferation marker indicating how fast cancer cells are dividing', 'Is the same as HER2', 'Has no prognostic value', 'Indicates benign disease',
'B', 'Ki-67: nuclear antigen present in dividing cells (proliferation marker). High Ki-67 (>20-30%) indicates more aggressive, faster-growing tumor. Helps distinguish luminal A (low Ki-67) from luminal B (high Ki-67). Prognostic value and may guide treatment decisions. Reference: Yerushalmi R. Lancet Oncol. 2010.',
'medium', 'knowledge'),

('c0000034-0000-0000-0000-000000000034', 'a0000003-0000-0000-0000-000000000003',
'Gene expression profiling tests like Oncotype DX:',
'Replace standard pathology', 'Help predict recurrence risk and chemotherapy benefit in ER-positive, HER2-negative early breast cancer', 'Are only research tools', 'Are used for metastatic cancer', 'Determine HER2 status',
'B', 'Oncotype DX: 21-gene recurrence score. Used in ER+/HER2-/node-negative (and some node-positive) early breast cancer. Provides recurrence risk and predicts chemotherapy benefit. Low recurrence score may safely avoid chemotherapy. Reference: Paik S. N Engl J Med. 2004.',
'hard', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 19 (Breast Diseases): 60 questions inserted' as status;
